Growth arrest-specific gene 6 (Gas6) levels are elevated in patients with chronic renal failure

Nephrology Dialysis Transplantation

Volumn 27, Issue 11, 2012, Pages 4166-4172

  Lee, Iris J ^a   Hilliard, Brendan ^a   Swami, Abhishek ^a   Madara, John C ^a   Rao, Swati ^a   Patel, Tapan ^a   Gaughan, John P ^b   Lee, Jean ^a   Gadegbeku, Crystal A ^a   Choi, Eric T ^b   Cohen, Philip L ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

chronic kidney disease; dialysis; Gas6; inflammation; mortality; vascular disease

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; GROWTH ARREST SPECIFIC PROTEIN 6; IRON; PROTEIN S;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; GROWTH ARREST SPECIFIC GENE 6; HEMODIALYSIS; HUMAN; INFLAMMATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROTEIN PRECURSORS; PROTEIN S; PROTHROMBIN; RENAL DIALYSIS;

EID: 84869413741     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs337     Document Type: Article

References (42)

1. Knight EL, Rimm EB, Pai JK et al. Kidney dysfunction, inflammation, and coronary events: a prospective study. J Am Soc Nephrol 2004; 15:1897-1903. (Pubitemid 38822070)
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
3. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285-1295. (Pubitemid 39258422)
4. Panichi V, Migliori M, De Pietro S et al. C-reactive protein and inter-leukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron 2002; 91:594-600. (Pubitemid 34914058)
5. Shlipak MG, Fried LF, Crump C et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107:87-92. (Pubitemid 36070938)
6. Descamps-Latscha B, Herbelin A, Nguyen AT et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 1995; 154:882-892.
7. Stitt TN, Conn G, Gore M et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 1995; 80:661-670.
8. Hafizi S, Dahlback B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 2006; 17:295-304. (Pubitemid 44038616)
9. Tjwa M, Bellido-Martin L, Lin Y et al. Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood 2008; 111:4096-4105.
10. Cosemans JM, Van Kruchten R, Olieslagers S et al. Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization. J Thromb Haemost 2010; 8:1797-1808.
11. Wallet MA, Sen P, Flores RR et al. MerTK is required for apoptotic cell-induced T cell tolerance. J Exp Med 2008; 205:219-232. (Pubitemid 351185728)
12. Seitz HM, Camenisch TD, Lemke G et al. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J Immunol 2007; 178:5635-5642. (Pubitemid 46674359)
13. Gibot S, Massin F, Cravoisy A et al. Growth arrest-specific protein 6 plasma concentrations during septic shock. Crit Care 2007; 11: R8
14. Wu J, Ekman C, Jonsen A et al. Increased plasma levels of the soluble Mer tyrosine kinase receptor in systemic lupus erythemato-sus relate to disease activity and nephritis. Arthritis Res Ther 2011; 13: R62.
15. Suh CH, Hilliard B, Li S et al. TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Res Ther 2010; 12: R146.
16. Ekman C, Jonsen A, Sturfelt G et al. Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythema-tosus. Rheumatology (Oxford) 2011; 50:1064-1069.
17. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol 2008; 8:327-336. (Pubitemid 351595219)
18. Rothlin CV, Lemke G. TAM receptor signaling and autoimmune disease. Curr Opin Immunol 2010; 22:740-746.
19. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001; 293:306-311. (Pubitemid 32694748)
20. Angelillo-Scherrer A, de Frutos P, Aparicio C et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 2001; 7:215-221. (Pubitemid 32148489)
21. Gould WR, Baxi SM, Schroeder R et al. Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses. J Thromb Haemost 2005; 3:733-741. (Pubitemid 41647888)
22. Fiebeler A, Park JK, Muller DN et al. Growth arrest specific protein 6/Axl signaling in human inflammatory renal diseases. Am J Kidney Dis 2004; 43:286-295. (Pubitemid 38146327)
23. Melaragno MG, Fridell YW, Berk BC. The Gas6/Axl system: a novel regulator of vascular cell function. Trends Cardiovasc Med 1999; 9:250-253.
24. Melaragno MG, Cavet ME, Yan C et al. Gas6 inhibits apoptosis in vascular smooth muscle: role of Axl kinase and Akt. J Mol Cell Cardiol 2004; 37:881-887. (Pubitemid 39222079)
25. Son BK, Kozaki K, Iijima K et al. Gas6/Axl-PI3K/Akt pathway plays a central role in the effect of statins on inorganic phosphate-induced calcification of vascular smooth muscle cells. Eur J Pharmacol 2007; 556:1-8 (Pubitemid 46073988)
26. Jiang L, Liu CY, Yang QF et al. Plasma level of growth arrest-specific 6 (GAS6) protein and genetic variations in the GAS6 gene in patients with acute coronary syndrome. Am J Clin Pathol 2009; 131:738-743.
27. Danziger J. Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol 2008; 3:1504-1510.
28. Barreto DV, Barreto FC, Liabeuf S et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 2009; 77:550-556.
29. Nolan CR. Strategies for improving long-term survival in patients with ESRD. J Am Soc Nephrol 2005; 16(Suppl 2): S120-S127 (Pubitemid 46173249)
30. Drueke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol 6:723-735.
31. Schlieper G, Westenfeld R, Kruger T et al. Circulating nonpho-sphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol, 22:387-395.
32. Pilkey RM, Morton AR, Boffa MB et al. Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis 2007; 49:432-439.
33. Yanagita M. Gas6, warfarin, and kidney diseases. Clin Exp Nephrol 2004; 8:304-309. (Pubitemid 40941105)
34. Yanagita M, Ishimoto Y, Arai H et al. Essential role of Gas6 for glomerular injury in nephrotoxic nephritis. J Clin Invest 2002; 110:239-246. (Pubitemid 34787361)
35. Ekman C, Gottsater A, Lindblad B et al. Plasma concentrations of Gas6 and soluble Axl correlate with disease and predict mortality in patients with critical limb ischemia. Clin Biochem 2011; 43:873-876.
36. Dart AM, Cooper B, Kay SB et al. Relationships between protein C, protein S, von Willebrand factor and euglobulin lysis time and cardiovascular risk factors in subjects with and without coronary heart disease. Atherosclerosis 1998; 140:55-64. (Pubitemid 28378454)
37. Rudnicka AR, Miller GJ, Nelson T et al. An association between plasma free protein s concentration and risk of coronary heart disease in middle-aged men. Thromb Res 2001; 101:1-11. (Pubitemid 32141175)
38. Guerin AP, London GM, Marchais SJ et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15:1014-1021. (Pubitemid 30410374)
39. Weiner DE, Tabatabai S, Tighiouart H et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 2006; 48:392-401. (Pubitemid 44247251)
40. Rothlin CV, Ghosh S, Zuniga EI et al. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007; 131:1124-1136. (Pubitemid 350235020)
41. Scutera S, Fraone T, Musso T et al. Survival and migration of human dendritic cells are regulated by an IFN-alpha-inducible Axl/Gas6 pathway. J Immunol 2009; 183:3004-3013.
42. Hafizi S, Dahlback B. Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J 2006; 273:5231-5244. (Pubitemid 44772384)